Kidney and haemostasis: A (personal) time-journey

Hamostaseologie

Volumn 35, Issue 1, 2015, Pages 73-76

  Andrassy, Konrad ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

FGF 23; Myocardial infarction; Uremic bleeding; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; FIBROBLAST GROWTH FACTOR 23; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ATRIAL FIBRILLATION; BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; NEPHROLOGY; PRACTICE GUIDELINE; REVIEW; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; HEMOSTASIS; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; KIDNEY FUNCTION TESTS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; THROMBOSIS; TREATMENT OUTCOME;

EID: 84939524661     PISSN: 07209355     EISSN: 25675761     Source Type: Journal    
DOI: 10.5482/hamo-14-08-0032     Document Type: Review

References (46)

1. Blumberg BS, Alter HJ, Visnich S. A "new "antigen in leukemia sera. J Amer Ass 1965; 191: 541-546.
2. Krugman S. Viral hepatitis: overview and historical perspectives. Yale J Biol Med 1976; 49:199-203.
3. Andrassy K, Ritz E, Sanwald R. Australia-Antigen-Nachweis in Fibrinogenkonzentraten und anderen gerinnungsaktiven Proteinen. Dtsch Med Wschr 1970; 95: 2467-2469.
4. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362-364.
5. Rath CE, Maillard JA, Schreiner GE. Bleeding tendency in uremia. New Engl J Med 1957; 257:808-811.
6. Vanholder R, DeSmet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
7. Weiner DE, Tighiouart H, Amin MG et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315.
8. Meijers BKI Bammens B De Moor B et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73:1174-1180.
9. Noris M, Benigni A, Boccardo P et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44: 445-450.
10. Sloand, EM, Sloand JA, Prodouz K et al. Reduction of platelet glycoprotein Ib in uraemia. Brit J Haematol 1991; 77: 375-381.
11. Gawaz, MP, Dobos G, Späth M et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994; 5: 36-46.
12. Boccardo P, Remuzzi G. Coagulation problems in dialysis patients. In: Lameire N, Mehta RL (eds). Complications of Dialysis. New York: Marcel Dekker 2000, 327-341.
13. Andrassy K, Ritz E, Hasper M et al. Penicillin-induced coagulation disorder. Lancet 1974; ii:1039-1041.
14. Andrassy K, Weischedel E, Ritz E et al. Bleeding in uremic patients after carbenicillin. Thromb Haemost 1976; 36: 115-126.
15. Spannagel M, Bauersachs R, Debus ES et al. Therapie mit Dabigatran. Hämostaseologie 2012; 32:294-305.
16. Laux V, Perzborn A, Heitmeier S et al. Direct inhibitors of coagulation proteins- the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Hamost 2009; 102: 892-899.
17. Bucha E, Kreml R, Nowak G. In -vitro study of r-hirudin permeability through membranes of different haemodialysers. Nephrol Dial Transplant 1999; 14: 2922-2926.
18. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 13: 461-470.
19. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
20. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. Kidney Disease: Improving global outcomes (KDIGO) CKD Work group. KDIGO 2012 Clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3 (Suppl): 1-150.
22. Lindeman RD. Overview: renal physiology and pathophysiology of aging. Am J Kidney Dis 1990; 16: 275-282.
23. Vanholder R, Glorieux G, van Bliesen W. Advantages of new hemodialysis membranes and equipment. Nephron Clin Pract 2010; 114: c165-c172.
24. Eschbach JW, Egriev JC, Downing MR et al. Correction of anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. New Engl J Med 1987; 316: 73-78.
25. Moia M, Mannucci PM, Vizzotto L et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; ii: 1227-1229.
26. Fusté B, Serradelli M, Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678-685.
27. Nauta ST, van Domburg RT, Nuis RJ et al. Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease: evolution from the prethrombolysis to the percutaneous coronary intervention. Kidney Int 2013: 84: 355-358.
28. Alonso A, Lopez FL, Matsushita K et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2011; 123: 2946-2953.
29. Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. New Engl J Med 2012: 36: 625-635.
30. Herzog CA, Asinger RW, Berger AK. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease improving global outcomes (KDIGO). Kidney Int 2011; 80: 572-586.
31. Hart G, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
32. Reinecke H, Brand E, Mesters R et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705-711.
33. Lega JC, Bertoletti L, Gremillet C et al. Consistency of safety profile of new anticoagulants in patients with renal failure, J Thromb Haemost 2014;12: 337-343.
34. Hohnloser SH, Hijazi Z, Thomas L et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation:insights from the ARISTOTLE trial. Europ Heart J 2012; 33: 2812-2830.
35. Koos R, Mahnken AH, Mühlenbruck,G et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computer tomography. Am J Cardiol 2005; 96:747-749.
36. Schurgers LJ, Joosen IA, Laufer EM et al. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012; 7: 1-14.
37. Krueger T, Westenfeld R, Ketteler M et al. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int 2009; 76: 18-22.
38. Cannata-Andia, JB, Fernandez-Martin, JL, Locatelli, F et al. Use of phosphate- binding agents is associated with a lower risk of mortality. Kidney Int 2013; 84: 998-1008.
39. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82:737-747.
40. Faul C, Amaral AP, Oskouel B et al. FGF 23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
41. Seiler S, Reichart B, Roth D et al. FGF - 23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25:3983-3989.
42. Arnlöv J, Carlsson AC, Sundström J et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2012; 83: 160-166.
43. Isakova T, Wahl p, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
44. Shearer MJ, Bechtold H, Andrassy K et al. Mechanism of cephalosporin-induced hypoprothrombinemia:relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1988; 28: 88-95.
45. Schurgers, LJ. Vitamin K: key vitamin in controlling vascular calcification. Kidney Int 2012; 83:782-784.
46. Westenfeld R, Krueger T, Schlieper G et al. Effect of Vitamin K2 supplementation on functional Vitamin K deficiency in haemodialysis patients: a randomized trial. Am J Kidney Dis 2012; 59:186-195.